Eli Lilly and Company (LLY) is expected to report third-quarter 2015 earnings today before the open. The Street has consensus estimates of $0.75 in earnings per share and $4.99 billion in revenue. In the Q3 of the previous year, the developer of pharmaceutical products posted $0.66 in EPS and $4.88 billion in revenue. Meanwhile, EarningsWhisper.com reports a whisper number of $0.79 per share.
As a quick reminder, LLY reported Q215 EPS of $0.90, $0.16 better than the Street’s consensus estimate of $0.74. Revs increased 0.81% on a year-over-year basis to $4.98 billion versus the $4.89 billion consensus.
On valuation measures, Eli Lilly & Co. shares have a T-12 price/sales ratio of 4.21 and a price/book for the same period of 5.63. EPS is $1.93. The name has a market cap of $85.50 billion and a median Wall Street price target of $92.50 with a high target of $118.00. Currently there are 11 analysts that rate LLY a ‘Buy’, 10 rate it a ‘Hold’. No analyst rates it a ‘Sell’.
In terms of share statistics, Eli Lilly & Co. has a total of 1.11 billion shares outstanding with 12.11% held by insiders and 63.50% held by institutions. The stock’s short interest currently stands at 1.20%, bringing the total number of shares sold short to 11.72 million.
Offering a dividend yield of 2.63%, shares of Indianapolis, Indiana-based company are up 26.69% year-over-year and 15.03% year-to-date.